NASDAQ · BJDX

Bluejay Diagnostics, Inc.

$1.01 -$0.02 (-1.94%) 1D Market open
Session Pulse Regular session 1 mentions on Wed No new SEC filings since Mon close its sector ranked 5/11 this week Full pulse →

Key Metrics

$1.07M
Market cap
P/E · TTM
Revenue · TTM
−$6.90M
Net income
EPS · TTM $-49.84
Dividend yield
Free cash flow −$6.62M
Beta · 1Y 0.93
EBITDA · TTM −$6.92M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jun 4 high, the share price fell 81%.

    Peak close $5.30 on Jun 4; trough close $1.03 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -81%
  • Jul 22
    A material event was filed (Form 8-K).

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 29
    The stock moved -50.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 29
  • Jun 2
    The stock moved +100.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.07M
Enterprise value
Shares outstanding1.0M
52-wk range$0.63 – $7.00
Avg volume · 20D593.5K
Net cash
Book value / share$30.19
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Bluejay Diagnostics, Inc.
IPO dateNov 10, 2021
Employees6

Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -165.1% · —

Financial Health

Current ratio2.81
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$2.55M

Cash Flow · TTM

Operating CF −$6.46M
Capex −$157.29K
Free cash flow −$6.62M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings